Product Details
Research-grade peptides with clear specifications, COA-backed quality verification, and Fahrenheit storage guidance for laboratory use.
FOXO4-DRI -10MG
Overview
FOXO4-DRI is a synthetic peptide designed to target and eliminate senescent cells—cells that have stopped dividing and contribute to aging and inflammation.
$125.00
Out of stock
Share this item
Description
FOXO4-DRI is a synthetic peptide designed to target and eliminate senescent cells—cells that have stopped dividing and contribute to aging and inflammation. It is derived from the natural FOXO4 protein, a transcription factor that regulates cell survival and stress responses. In its natural form, FOXO4 binds to p53 inside cells, helping regulate whether a cell survives or undergoes programmed cell death. By modifying FOXO4 into FOXO4-DRI, the peptide competes with endogenous FOXO4 for binding to p53. This disruption selectively triggers apoptosis in senescent cells, allowing healthy cells to remain unharmed. As a result, FOXO4-DRI is studied for its ability to rejuvenate tissues by removing these aging cells, potentially restoring youthful cellular function, improving tissue health, and reducing chronic inflammation.
FOXO4-DRI Research Details
FOXO4-DRI is a research peptide from senescence biology literature. The central model is that FOXO4 interaction with p53 supports survival of senescent cells; disrupting that interaction has been studied as a way to investigate senescent-cell apoptosis and tissue-aging phenotypes in preclinical systems.
99%+ target purity or lot-specific COA value
FOXO4 D-retro-inverso peptide; verify exact sequence by COA
Lyophilized research material unless otherwise specified by COA
Research use only
Research Background
Cell-penetrating D-retro-inverso peptide designed to disrupt FOXO4-p53 interaction in senescence research models. Key OneBio research contexts include cellular senescence assays, p53/foxo4 pathway studies, apoptosis models, and aging-biology research.
Specifications
| Compound | FOXO4-DRI |
| SKU / Product | foxo4 |
| Molecular Weight | Lot-specific; commonly reported ~4 kDa range |
| Formula / Classification | Lot-specific |
| Database / Identity Note | No standardized PubChem record confirmed; verify by COA |
| Storage | -4°F long-term; 35-46°F short-term refrigerated; 39°F after reconstitution for up to 30 days when appropriate for the research protocol |
Quality Verification
Each batch should be reviewed against its Certificate of Analysis, including identity confirmation, purity method, mass/sequence or component confirmation, appearance, and lot-specific handling notes. Blend products should be checked against component-ratio documentation where available.
Laboratory Preparation
Prepare only inside a qualified laboratory using validated solvent choice, concentration, sterility, and storage protocols. For lyophilized peptides, use sterile deionized water or bacteriostatic water when appropriate for the research protocol, mix gently, maintain cold-chain handling, and avoid repeated freeze-thaw cycles.
Product-Specific Q&A
What is FOXO4-DRI used for in research?
FOXO4-DRI is used as a research material for cellular senescence assays, p53/foxo4 pathway studies, apoptosis models, and aging-biology research. It is not offered for diagnostic, therapeutic, clinical, veterinary, or human-use applications.
What mechanism is most relevant for FOXO4-DRI?
Cell-penetrating D-retro-inverso peptide designed to disrupt FOXO4-p53 interaction in senescence research models.
How should FOXO4-DRI identity and purity be verified?
Use the lot-specific Certificate of Analysis to confirm identity, purity, mass/sequence or component profile, and any method-specific data such as LC-MS/HPLC. Technical values on this page are research references and should be checked against the delivered lot.
What storage conditions apply to FOXO4-DRI?
-4°F long-term; 35-46°F short-term refrigerated; 39°F after reconstitution for up to 30 days when appropriate for the research protocol. Keep sealed, dry, protected from light, and avoid repeated freeze-thaw cycles after preparation.
References
- PMID 36515093: Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation 2023.
- PMID 40593617: The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature communications 2025.
- PMID 39994346: FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications biology 2025.
Expanded Product Information
PeptideTech-style product tools added beneath the existing OneBio product layout: tabs, specifications, COA guidance, shipping/storage information, stock-solution guidance, verification notes, and FAQ.
| Product | Current product |
|---|---|
| Form | Lyophilized research material unless otherwise stated on the product label. |
| Purity / Identity | See product listing and available COA/batch documentation. |
| Storage | Long-term freezer storage around -4°F. Short-term refrigerated storage 35–46°F. Reconstituted materials should be handled under validated laboratory protocols. |
| Use Standard | Research-use only; not for human or animal administration. |
Third-party verification: Review the available Certificate of Analysis and batch documentation before use. Verify identity, purity, appearance, and lot-specific details against your lab requirements.
Are these products for research use only?
Yes. OneBio Research products are sold strictly for laboratory research and analytical testing.
Where do I find storage guidance?
Use the product label, COA, and the storage tab above. Long-term freezer storage is commonly referenced around -4°F; refrigerated short-term storage is 35–46°F.
Can I request documentation?
Yes. Use the COA/documentation request link or contact OneBio Research with the product and lot details.
Reviews
There are no reviews yet.